PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
9114909-2	1993	The influence of interferon-alpha (IFN alpha) on the clearances of theophylline (TH), antipyrine (AP) and hexobarbitone (HB) was studied in seven cancer patients given IFN alpha as their only treatment.	Hexobarbital	106-119	interferon alpha 1	Homo sapiens	35-44
6149777-4	1984	TRH appeared to bean antagonist of atropine and physostigmine by locomotor activity and hypnotic effect of hexenal and to be an agonist of phenylephrine, isadrin, amphetamine and an antagonist of phentolamine and propranolol as shown by behavioral tests.	Hexobarbital	107-114	thyrotropin releasing hormone	Mus musculus	0-3
8457584-5	1993	AIA administration to the animals caused inhibition of hexobarbital-promoted electron flow from NADPH-cytochrome P-450 reductase to phenobarbital-inducible ferricytochrome P-450 both in microsomal particles and reconstituted systems.	Hexobarbital	55-67	NADPH--cytochrome P450 reductase	Oryctolagus cuniculus	96-128
1728399-3	1992	The administration of IL-2 alone or in combination with IFN-alpha or IFN-gamma causes dose-dependent increases in hexobarbital-induced sleep times.	Hexobarbital	114-126	interleukin 2	Mus musculus	22-26
1728399-3	1992	The administration of IL-2 alone or in combination with IFN-alpha or IFN-gamma causes dose-dependent increases in hexobarbital-induced sleep times.	Hexobarbital	114-126	interferon alpha	Mus musculus	56-65
1728399-3	1992	The administration of IL-2 alone or in combination with IFN-alpha or IFN-gamma causes dose-dependent increases in hexobarbital-induced sleep times.	Hexobarbital	114-126	interferon gamma	Mus musculus	69-78
1768567-6	1991	oral clearance of S-(+) hexobarbitone was 1.9 +/- 0.3 and 1.8 +/- 0.2 ml min-1 kg-1, respectively, in young and elderly subjects and increased approximately six fold following 14 days of rifampicin treatment in both young (to 11.9 +/- 2.2 ml min-1 kg-1) and elderly (to 10.7 +/- 2.8 ml min-1 kg-1) subjects.	Hexobarbital	18-37	CD59 molecule (CD59 blood group)	Homo sapiens	73-83
1768567-6	1991	oral clearance of S-(+) hexobarbitone was 1.9 +/- 0.3 and 1.8 +/- 0.2 ml min-1 kg-1, respectively, in young and elderly subjects and increased approximately six fold following 14 days of rifampicin treatment in both young (to 11.9 +/- 2.2 ml min-1 kg-1) and elderly (to 10.7 +/- 2.8 ml min-1 kg-1) subjects.	Hexobarbital	18-37	CD59 molecule (CD59 blood group)	Homo sapiens	242-252
1768567-6	1991	oral clearance of S-(+) hexobarbitone was 1.9 +/- 0.3 and 1.8 +/- 0.2 ml min-1 kg-1, respectively, in young and elderly subjects and increased approximately six fold following 14 days of rifampicin treatment in both young (to 11.9 +/- 2.2 ml min-1 kg-1) and elderly (to 10.7 +/- 2.8 ml min-1 kg-1) subjects.	Hexobarbital	18-37	CD59 molecule (CD59 blood group)	Homo sapiens	242-252
2669966-1	1989	The human liver cytochrome P-450 (P-450) proteins responsible for catalyzing the oxidation of mephenytoin, tolbutamide, and hexobarbital are encoded by a multigene family (CYP2C).	Hexobarbital	124-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
2771871-2	1989	All compounds prolonged hexobarbital-induced sleeping time in a dose-dependent manner (doses 3.0 and 30.0 mg/kg, except nifedipine 0.3 and 3.0 mg/kg) and inhibited cytochrome P450-dependent N-demethylation of aminopyrine in vitro in rat liver microsomes.	Hexobarbital	24-36	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	164-179
2458634-6	1988	Like binding of [35S]TBPS to the gamma-aminobutyric acid (GABA) receptor, its binding to Torpedo membranes was inhibited by pentobarbital, mephobarbital, and hexobarbital (IC50 of 85, 225, and 300 microM), respectively), but not by phenobarbital.	Hexobarbital	158-170	GABA type A receptor-associated protein	Homo sapiens	33-72
3259924-1	1988	Addition of hexobarbital (1 mM) to the culture medium of rat hepatocytes protected against the rapid decline in the level of cytochrome P-450 and the activities of various drug metabolizing enzymes.	Hexobarbital	12-24	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	125-141
3436431-1	1987	It was shown that single doses of levamisole (10 mg/kg) and dibasole (50 and 100 mg/kg) suppressed the activity of cytochrome P-450 that was indicated by an increase of hexenal-induced sleep in mice.	Hexobarbital	169-176	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	115-131
3676462-2	1987	The in vivo experiments have revealed a considerably increased duration of sleep in mice treated with hexenal after the administration of different Cu-2 doses.	Hexobarbital	102-109	immunoglobulin kappa variable 1-35	Mus musculus	148-152
2438009-0	1987	Effects of aldehyde dehydrogenase inhibitors on hexobarbital sensitivity and neuroamine metabolism in rat brain.	Hexobarbital	48-60	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	11-33
2438009-1	1987	Several authors have found that the aldehyde dehydrogenase (ALDH) inhibitor, disulfiram, prolongs hexobarbital-induced anaesthesia.	Hexobarbital	98-110	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	36-58
2438009-1	1987	Several authors have found that the aldehyde dehydrogenase (ALDH) inhibitor, disulfiram, prolongs hexobarbital-induced anaesthesia.	Hexobarbital	98-110	aldehyde dehydrogenase 3 family, member A1	Rattus norvegicus	60-64
3101674-2	1986	The presence of a very active cytochrome P-450-dependent drug-metabolizing system in the olfactory epithelium has been confirmed by using 7-ethoxycoumarin, 7-ethoxyresorufin, hexobarbitone and aniline as substrates, and the reasons for the marked activity of the cytochrome P-450 in this tissue have been investigated.	Hexobarbital	175-188	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	30-46
3746810-10	1986	All active compounds that we tested in this series, as well as denzimol and nafimidone, potentiated hexobarbital-induced sleeping time in mice, probably by imidazole-mediated inhibition of cytochrome P-450.	Hexobarbital	100-112	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	189-205
3746811-6	1986	Oxidation of the 4-alkyl compounds led not only to the loss of P-450NF but also to decreases in catalytic activities of cytochrome P-450 isozymes catalyzing other reactions (phenacetin O-deethylation and hexobarbital 3"-hydroxylation).	Hexobarbital	204-216	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	120-136
3705086-8	1986	The initial effect of MeHgOH was found closely related to the decrease in the rate of hexobarbital metabolism in the liver through lowering of cytochrome P-450 concentration.	Hexobarbital	86-98	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	143-159
3148724-8	1988	When reconstituted with NADPH-cytochrome P-450 reductase and dilauroylphosphatidylcholine, cytochromes P-450b and P-450b* catalyzed the N-demethylation of benzphetamine and aminopyrine, the 4-hydroxylation of aniline, the O-dealkylation of 7-ethoxycoumarin, the 3-hydroxylation of hexobarbital, and the 6-hydroxylation of zoxazolamine.	Hexobarbital	281-293	cytochrome p450 oxidoreductase	Rattus norvegicus	24-56
3148724-8	1988	When reconstituted with NADPH-cytochrome P-450 reductase and dilauroylphosphatidylcholine, cytochromes P-450b and P-450b* catalyzed the N-demethylation of benzphetamine and aminopyrine, the 4-hydroxylation of aniline, the O-dealkylation of 7-ethoxycoumarin, the 3-hydroxylation of hexobarbital, and the 6-hydroxylation of zoxazolamine.	Hexobarbital	281-293	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	103-109
3148724-8	1988	When reconstituted with NADPH-cytochrome P-450 reductase and dilauroylphosphatidylcholine, cytochromes P-450b and P-450b* catalyzed the N-demethylation of benzphetamine and aminopyrine, the 4-hydroxylation of aniline, the O-dealkylation of 7-ethoxycoumarin, the 3-hydroxylation of hexobarbital, and the 6-hydroxylation of zoxazolamine.	Hexobarbital	281-293	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	114-120
3572983-5	1987	All these compounds were potent potentiators of hexobarbital-induced sleeping time in mice, presumably via the well-known imidazole-mediated inhibition of cytochrome P-450.	Hexobarbital	48-60	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	155-171
3125861-2	1987	It has been shown that hexenal causes the decrease of blood ph and p50 of hemoglobin, ethanol causes the increase of blood ph and p50.	Hexobarbital	23-30	Y-box-binding protein 1	Oryctolagus cuniculus	67-70
6149908-4	1984	The pharmacokinetic sequelae of the previously observed post-traumatic decrease in cytochrome P-450 content were demonstrated, using hexobarbital and zoxazolamine as model cytochrome P-450-oxidized drugs.	Hexobarbital	133-145	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	83-99
6149909-4	1984	In vitro drug metabolism studies with hexobarbital and zoxazolamine as substrates confirmed the post-traumatic depression of the cytochrome P-450-catalyzed oxidation of these drugs which was suggested by previous in vivo pharmacokinetic studies.	Hexobarbital	38-50	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	129-145
6733159-1	1984	The effects of the phospholipid composition of rat liver microsomes on the differential binding spectra of cytochrome P-450 with type I and II substrates (hexobarbital and aniline) were studied.	Hexobarbital	155-167	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	107-123
6469956-2	1984	The substrates hexobarbital and ethylbenzene have been shown to compete for the spectral binding site of phenobarbital-induced rat hepatic microsomal cytochrome p-450.	Hexobarbital	15-27	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	150-166
6420404-5	1984	Cytochrome P-450h is a versatile catalyst exhibiting high activity toward benzphetamine, hexobarbital, and estradiol-17 beta and moderate activity toward benzo[alpha]pyrene and zoxazolamine.	Hexobarbital	89-101	cytochrome P450, subfamily 2, polypeptide 11	Rattus norvegicus	0-17
6805483-0	1982	Thyroliberin (thyrotropin releasing hormone): antagonism of halothane and hexobarbital narcosis in mice.	Hexobarbital	74-86	thyrotropin releasing hormone	Mus musculus	0-43
6888166-2	1983	The results indicate that the in vitro interaction of hexobarbital and SKF-525 A (type I binding compounds) with microsomal cytochrome p-450 inhibits the peroxidase activity while the in vitro interaction of aniline (type II binding compound) only slightly affect the peroxidase activity.	Hexobarbital	54-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	124-140
6630164-0	1983	Effect of 2,4-dinitrophenol on the oxidative metabolism of hexobarbital by cytochrome P-450 in perfused rat liver.	Hexobarbital	59-71	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	75-91
6830852-3	1983	Caffeine addition (in vitro) to partially purified cytochrome P-450 altered the hexobarbital, aniline and ethylisocyanide induced spectral change, and decreased NADPH oxidation in presence of substrates aminopyrine and acetanilide.	Hexobarbital	80-92	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	51-67
6805483-3	1982	TRH shortened dose-dependently the halothane and hexobarbital sleeping-time with ED50 values of 3.1 and 6.6 mg/kg s.c., respectively.	Hexobarbital	49-61	thyrotropin releasing hormone	Mus musculus	0-3
7121136-4	1982	Halothane and hexobarbitone also inhibited mitochondrial Ca2+ uptake in vivo.	Hexobarbital	14-27	carbonic anhydrase 2	Rattus norvegicus	57-60
7309741-1	1981	The spectral changes of cytochrome P-450 associated with mixed-function oxidation of hexobarbital and aminopyrine were investigated in perfused rat liver, using reflectance spectrophotometry.	Hexobarbital	85-97	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	24-40
7252836-0	1981	Heme enhances hexobarbital metabolism in perfused rat liver after drug-mediated destruction of cytochrome P-450.	Hexobarbital	14-26	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	95-111
7285242-4	1981	The binding of type I compounds, hexobarbital and androstanedione, with cytochrome P-450, as determined by the magnitude of the type I spectral change of microsomes, was markedly enhanced at alkaline pH compared to that at acid pH.	Hexobarbital	33-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	72-88
7252836-7	1981	Heme administered after AIA significantly accelerated hexobarbital disappearance from the perfusate, reflecting increased hexobarbital metabolism by reconstituted cytochrome P-450.	Hexobarbital	122-134	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	163-179
26689857-0	2016	Duration of hexobarbital-induced sleep and monoamine oxidase activities in rat brain: Focus on the behavioral activity and on the free-radical oxidation.	Hexobarbital	12-24	monoamine oxidase A	Rattus norvegicus	43-60
6968297-5	1980	Hexobarbital hydroxylating activity and binding capacity of P-450 for hexobarbital, which were strikingly decreased after alpha-irradiation were less protected by radical scavengers, in contrast to the case of the lipid peroxidation and of the enzymes.	Hexobarbital	70-82	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	60-65
5067380-0	1972	Oxidation and glucuronidation of certain drugs in various subcellular fractions of rat liver: binding of desmethylimipramine and hexobarbital to cytochrome P-450 and oxidation and glucuronidation of desmethylimipramine, aminopyrine, p-nitrophenol and 1-naphthol.	Hexobarbital	129-141	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	145-161
5968073-2	1966	Inhibition of hexobarbital metabolism in the intact rat and in the isolated perfused liver by 2-diethylaminoethyl 2,2-diphenylvalerate HC1 (SKF 525-A) and its N-deethylated derivatives.	Hexobarbital	14-26	Hypercalciuria QTL 1	Rattus norvegicus	135-138
21064417-0	1946	The effect of pentobarbital sodium, evipal sodium and demerol on the action of insulin.	Hexobarbital	36-49	insulin	Homo sapiens	79-86
33428920-9	2021	Furthermore, an NQ cocktail (2.5 muM each) that does not activate Nrf2 enhanced hexenal-mediated Nrf2 activation.	Hexobarbital	80-87	NFE2 like bZIP transcription factor 2	Homo sapiens	97-101
1021219-1	1976	Mephenytoin, diphenylhydantoin, pheneturide, and phenobarbital produced a concentration-dependent inhibition in the binding of hexobarbital to cytochrome P-450 at the type 1 site, while sulthiame slightly potentiated, and ethosuximide did not affect the binding characteristic of hexobarbital.	Hexobarbital	127-139	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
1021219-1	1976	Mephenytoin, diphenylhydantoin, pheneturide, and phenobarbital produced a concentration-dependent inhibition in the binding of hexobarbital to cytochrome P-450 at the type 1 site, while sulthiame slightly potentiated, and ethosuximide did not affect the binding characteristic of hexobarbital.	Hexobarbital	280-292	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	143-159
983613-0	1976	The binding of hexobarbital and aniline to cytochrome P-450 of liver microsomes from control and phenobarbital-treated rats of different ages.	Hexobarbital	15-27	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	43-59
983613-1	1976	The spectral changes due to the binding of hexobarbital and aniline to cytochrome P-450 of rat liver microsomes were investigated in 10-day- to 15-month-old rats.	Hexobarbital	43-55	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	71-87
1246040-1	1976	The effect of aromatic nitro compounds on the oxidative metabolism of representative type I (hexobarbital and aminopyrene) and type II (aniline and zoxazolamine) substrates by cytochrome P-450 dependent liver enzymes was studied.	Hexobarbital	93-105	cytochrome P-450	Oryctolagus cuniculus	176-192
1210995-4	1975	The addition of hexobarbital or ethylmorphine to microsomal suspension accelerates the reduction of cytochrome P-450 in some age groups only.	Hexobarbital	16-28	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	100-116
13912319-0	1962	Modification of hexobarbitone action by insulin.	Hexobarbital	16-29	insulin	Homo sapiens	40-47
28653655-2	2017	The data obtained in this study, using the microsomal oxidation inhibitor SKF525, and using animals with different duration of hexobarbital sleep, has shown that increased intensity of microsomal oxidation might be associated with increased MAO activity.	Hexobarbital	127-139	monoamine oxidase A	Rattus norvegicus	241-244
20382895-5	2010	To address this possibility, we have overexpressed the omega-3 fatty acid desaturases FAD3 and FAD7 that catalyze the conversion of linoleic acid (18:2) to linolenic acid (18:3), the precursor of hexenals and its derived alcohols.	Hexobarbital	196-204	omega-3 fatty acid desaturase	Solanum lycopersicum	95-99
24601081-5	2013	The prolongation of hexobarbital-induced sleeping time by carbon tetrachloride (CCl4) administration to mice was significantly reduced after pretreatment with AE-PA at 500 mg/kg b.w., proving the protective effect of the extract on microsomal drug-metabolizing enzyme.	Hexobarbital	20-32	chemokine (C-C motif) ligand 4	Mus musculus	80-84
17410408-6	2007	Toxic effect of CCl(4) was evident on CYP 2E1 activity by increased hexobarbitone induced sleep time and bromosulphalein retention.	Hexobarbital	68-81	C-C motif chemokine ligand 4	Rattus norvegicus	16-22
17410408-6	2007	Toxic effect of CCl(4) was evident on CYP 2E1 activity by increased hexobarbitone induced sleep time and bromosulphalein retention.	Hexobarbital	68-81	cytochrome P450, family 2, subfamily e, polypeptide 1	Rattus norvegicus	38-45
15347800-5	2004	The specific depletion of TomloxC in transgenic tomatoes led to a marked reduction in the levels of known flavor volatiles, including hexanal, hexenal, and hexenol, to as little as 1.5% of those of wild-type controls following maceration of ripening fruit.	Hexobarbital	143-150	lipoxygenase	Solanum lycopersicum	26-33
16258015-0	2005	Variations in CYP74B2 (hydroperoxide lyase) gene expression differentially affect hexenal signaling in the Columbia and Landsberg erecta ecotypes of Arabidopsis.	Hexobarbital	82-89	hydroperoxide lyase 1	Arabidopsis thaliana	14-21
16104814-3	2005	Here, we examined the effects of LOX 3 on hexenal formation from linolenic acid homogenized with watermelon 13-hydroperoxide lyase (HL)-overexpressing Nicotiana tabacum leaves and soybean acetone powder.	Hexobarbital	42-49	linoleate 9S-lipoxygenase-4	Glycine max	33-36
16104814-4	2005	Compared to the wild type, which contains LOXs 1, 2, and 3, the elimination of LOX 3 in LOX 1 + 2 facilitates greater production of hexenals.	Hexobarbital	132-140	seed linoleate 9S-lipoxygenase-2	Glycine max	42-58
16104814-4	2005	Compared to the wild type, which contains LOXs 1, 2, and 3, the elimination of LOX 3 in LOX 1 + 2 facilitates greater production of hexenals.	Hexobarbital	132-140	seed linoleate 9S-lipoxygenase-3	Glycine max	79-84
16104814-4	2005	Compared to the wild type, which contains LOXs 1, 2, and 3, the elimination of LOX 3 in LOX 1 + 2 facilitates greater production of hexenals.	Hexobarbital	132-140	linoleate 9S-lipoxygenase-4	Glycine max	42-45
16104814-5	2005	The use of LOX 2 alone yielded the highest hexenal production, while a two-step conversion was required for LOX 1 to produce hexenals at high levels due to different pH optima of the enzymes involved.	Hexobarbital	43-50	seed linoleate 9S-lipoxygenase-2	Glycine max	11-16
16104814-5	2005	The use of LOX 2 alone yielded the highest hexenal production, while a two-step conversion was required for LOX 1 to produce hexenals at high levels due to different pH optima of the enzymes involved.	Hexobarbital	43-50	linoleate 9S-lipoxygenase-4	Glycine max	11-14
16104814-5	2005	The use of LOX 2 alone yielded the highest hexenal production, while a two-step conversion was required for LOX 1 to produce hexenals at high levels due to different pH optima of the enzymes involved.	Hexobarbital	125-133	linoleate 9S-lipoxygenase-4	Glycine max	11-14
16104814-6	2005	These results clearly demonstrate that the soybeans lacking LOX 3 in combination with watermelon HL-overexpressing leaf tissues greatly enhance hexenal formation.	Hexobarbital	144-151	seed linoleate 9S-lipoxygenase-3	Glycine max	60-65
16608168-2	2006	Hexenal has demonstrated mutagenicity and genotoxicity in vitro and reacts with deoxyguanosine to form diastereomeric hexenal-derived exocyclic 1,N(2)-propanodeoxyguanosine (Hex-PdG) adducts.	Hexobarbital	118-125	hematopoietically expressed homeobox	Rattus norvegicus	0-3
16608168-4	2006	An LC/MS/MS assay for the quantitation of Hex-PdG, using [(13)C4(15)N2]Hex-PdG as an internal standard, was developed, to assess binding of hexenal to DNA.	Hexobarbital	140-147	hematopoietically expressed homeobox	Rattus norvegicus	42-45
16608168-8	2006	Hex-PdG was detected in ctDNA treated with 0.021 microM, 0.21 microM, or 2.1 mM hexenal but not in untreated DNA.	Hexobarbital	80-87	hematopoietically expressed homeobox	Rattus norvegicus	0-3
16608168-10	2006	Hex-PdG was not detected in DNA of untreated rat liver, but Hex-PdG in hexenal-treated calf thymus DNA was quantifiable when spiked into the rat liver DNA at 0.035 or 0.35 fmol/microg DNA.	Hexobarbital	71-78	hematopoietically expressed homeobox	Rattus norvegicus	60-63
14732275-4	2004	Both O9 and T16 plants were found to have a two-fold increase in 13-lipoxygenase (13-LOX) activity, which catalyzes the first of two steps leading to hexenal production from 18:3.	Hexobarbital	150-157	probable linoleate 9S-lipoxygenase 5	Nicotiana tabacum	85-88
15099849-5	2004	It also shortened hexobarbitone-induced sleeping time in mice, which was increased by CCl4 treatment, besides showing significant antilipid peroxidant effect in vitro.	Hexobarbital	18-31	chemokine (C-C motif) ligand 4	Mus musculus	86-90
11345489-2	2000	Moreover, SL-3 shortened hexobarbital-induced sleeping time, and SL-1 showed anticonvulsant activity in pentetrazole-induced seizures.	Hexobarbital	25-37	matrix metallopeptidase 11	Mus musculus	10-14
12105957-4	2002	In contrast to plant extracts, generally used as enzyme sources, high molar conversions were obtained with recombinant hydroperoxide lyase (50% for hexanal and 26% for hexenal formation), and no side products were formed.	Hexobarbital	168-175	9-divinyl ether synthase-like	Glycine max	119-138
14578118-4	2003	Regional cerebral blood flow (rCBF) in the prepyriform area (the primary olfactory cortex) was commonly increased by the passive application of odor: acetic acid, isoamylacetate or hexenol/hexenal.	Hexobarbital	189-196	CCAAT/enhancer binding protein zeta	Rattus norvegicus	30-34
14578118-8	2003	These findings suggest that the increase of rCBF in the anterior cingulate gyrus by the odor of hexenol/hexenal may contribute the healing effects of this mixture observed in the monkey.	Hexobarbital	104-111	CCAAT/enhancer binding protein zeta	Rattus norvegicus	44-48
14734831-5	2003	Release of cytochrome c from mitochondria into the cytosol, concomitant with activation of caspase-3 and -9, was also found in hexenal-treated groups.	Hexobarbital	127-134	caspase 3	Mus musculus	91-107
10886465-8	2000	CYP2C19 enzyme participates in the metabolism of omeprazole, propranolol and psychotropic drugs such as hexobarbital, diazepam, citalopram, imipramine, clomipramine and amitriptyline.	Hexobarbital	104-116	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	0-7
9208178-3	1997	The mass-spectrometric data indicate that cytochrome c becomes modified with one or two molecules of hexenal as the major reaction product.	Hexobarbital	101-108	cytochrome c, somatic	Equus caballus	42-54
8577203-5	1995	ET-1 and ET-3 produced central depressive effects demonstrated by depressive behavior signs, decrease of the spontaneous and amphetamine-stimulated motor activity, and prolongation of the hexobarbital-induced narcosis.	Hexobarbital	188-200	endothelin 1	Mus musculus	0-4
8548776-5	1996	The formation of hydroxydocetaxel was strongly reduced by CYP3A inhibitors such as ketoconazole, midazolam, erythromycin, testosterone, orphenadrine, and troleandomycin, whereas quinidine (CYP2D6), hexobarbital, tolbutamide, and mephenytoin (CYP2C) had no or little effect.	Hexobarbital	198-210	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	58-63
8577203-5	1995	ET-1 and ET-3 produced central depressive effects demonstrated by depressive behavior signs, decrease of the spontaneous and amphetamine-stimulated motor activity, and prolongation of the hexobarbital-induced narcosis.	Hexobarbital	188-200	endothelin 3	Mus musculus	9-13
7965056-5	1994	Like the rho 1 subunit, the currents generated by rho 2 are insensitive to GABAA receptor modulators including bicuculline, hexobarbital, and diazepam and can be reversibly inhibited by ZnCl2.	Hexobarbital	124-136	gamma-aminobutyric acid type A receptor subunit rho2	Homo sapiens	50-55
8010984-4	1994	In agreement, this supraphysiological expression of CYP2C12 was reflected at a pharmacologic level by a simultaneous elevation in in vitro and in vivo hexobarbital metabolism.	Hexobarbital	151-163	cytochrome P450, family 2, subfamily c, polypeptide 12	Rattus norvegicus	52-59